

DR REDDYS LABORATORIES LTD

Form 6-K

February 14, 2013

[Table of Contents](#)

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

February 2013

Commission File Number 1-15182

# DR. REDDY S LABORATORIES LIMITED

(Name of Registrant)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Andhra Pradesh 500 034, India

+91-40-4900-2900

Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

(Address of Principal Executive Offices)

Indicate by check mark whether registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's home country), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If Yes is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b):

Not applicable.

**Table of Contents**

**Table of Contents**

(1) Press Release, Dr. Reddy's Q3 & H1 9 months Financial Results, February 14, 2013.

**Table of Contents**

**Press Release**

Dr. Reddy s Laboratories Ltd.  
8-2-337, Road No. 3  
Banjara Hills, Hyderabad 500 034  
Andhra Pradesh, India  
  
Tel: 91-40-4900-2900  
Fax: 91-40-4900-2999  
  
[www.drreddys.com](http://www.drreddys.com)

**Dr. Reddy s Q3 & H1 9 months Financial Results**

**Q3 FY13 Revenues at 28.7 billion**  
*(YoY growth of 23%)#*

**9 months FY13 Revenues at 82.9 billion**  
*(YoY growth of 26%)#*

**Q3 FY13 EBITDA at 6.0 billion**

**9 months FY13 EBITDA at 18.6 billion**

**\*Adjusted Q3 FY13 PAT at 3.6 billion**

**\*\*Adj 9 months FY13 PAT at 11.3 billion**

**Hyderabad, India, February 14, 2013:** Dr. Reddy s Laboratories Ltd. (NYSE: RDY) today announced its unaudited consolidated financial results for the quarter ended December 31, 2012 under International Financial Reporting Standards (IFRS).

**KEY HIGHLIGHTS (Q3 FY13)**

**Consolidated revenues for Q3 FY13 at 28.7 billion, recorded YoY growth of 23%#. Consolidated revenues for 9 months FY13 at 82.9 billion, recorded YoY growth of 26%#.**

Revenues from the Global Generics segment for Q3 FY13 at 20.8 billion, recorded a YoY growth of 24%# primarily driven by North America and the Emerging market territories.

Revenues from the PSAI segment for Q3 FY13 at 7.1 billion, recorded YoY growth of 28%.

**EBITDA for Q3 FY13 at 6.0 billion, 21% of revenues. EBITDA for 9 months FY13 at 18.6 billion, 22% of the revenues.**

**PAT for Q3 FY13 at 3.8 billion, 13% of revenues. PAT for 9 months at 11.1 billion, 13% of revenues.**

**\*Adjusted PAT for Q3 FY13 at 3.6 billion, 13% of revenues.**

**During the quarter, the company launched 17 new products, filed 13 new product registrations and filed 13 DMFs globally.**

# *Excluding the impact of the olanzapine profit share recorded in Q3 FY12*

\* *Adjusted for tax normalization on account of the annual effective tax rate*

\*\* *Adjusted for (a) impairment charges in Q2 FY13 and (b) tax normalization on account of the annual effective tax rate.*



**Table of Contents**

All figures in millions, except EPS

All US dollar figures based on convenience translation rate of 1USD = 54.86

**Dr. Reddy s Laboratories Limited and Subsidiaries****Unaudited Consolidated Income Statement**

Particulars	Q3 FY13			Q3 FY12			Growth	
	(\$)	(Rs.)	%	(\$)	(Rs.)	%	%	
<b>Revenue</b>	<b>522</b>	<b>28,651</b>	<b>100</b>	<b>505</b>	<b>27,692</b>	<b>100</b>	<b>3</b>	
Cost of revenues	247	13,559	47	203	11,117	40	22	
<b>Gross profit</b>	<b>275</b>	<b>15,092</b>	<b>53</b>	<b>302</b>	<b>16,575</b>	<b>60</b>	<b>(9)</b>	
<b>Operating Expenses</b>								
Selling, general & administrative expenses	156	8,571	30	140	7,679	28	12	
Research and development expenses	37	2,026	7	28	1,514	5	34	
Other operating (income) / expense	(4)	(233)	(1)	(3)	(165)	(1)	41	
<b>Results from operating activities</b>	<b>86</b>	<b>4,728</b>	<b>17</b>	<b>138</b>	<b>7,547</b>	<b>27</b>	<b>(37)</b>	
Net finance (income) / expense	2	96	0	(3)	(174)	(1)	NC	
Share of (profit) / loss of equity accounted investees	(1)	(32)	(0)	(0)	(26)	(0)	23	
<b>Profit before income tax</b>	<b>85</b>	<b>4,664</b>	<b>16</b>	<b>141</b>	<b>7,747</b>	<b>28</b>	<b>(40)</b>	
Income tax expense	16	882	3	48	2,617	9	(66)	
<b>Profit for the period</b>	<b>69</b>	<b>3,782</b>	<b>13</b>	<b>94</b>	<b>5,130</b>	<b>19</b>	<b>(26)</b>	
<b>Diluted EPS</b>	<b>0.4</b>	<b>22.20</b>		<b>0.5</b>	<b>30.16</b>		<b>(26)</b>	

**PROFIT COMPUTATION:**

EBITDA Computation	Q3 FY13		Q3 FY12	
	(\$)	( )	(\$)	( )
<b>PBT</b>	85	4,664	141	7,747
Net Interest Expenses / (Income)	(0)	(13)	3	155
Depreciation	18	971	16	899
Amortization	7	411	7	408
<b>Reported EBITDA</b>	<b>110</b>	<b>6,033</b>	<b>168</b>	<b>9,209</b>

Adjusted PAT Computation	Q3 FY13		Q3 FY12	
	(\$)	( )	(\$)	( )
<b>PAT (reported)</b>	<b>69</b>	<b>3,782</b>	<b>94</b>	<b>5,130</b>
Adjustments:				
Tax adjustment*	(3)	(138)	16	852
<b>Adjusted PAT</b>	<b>66</b>	<b>3,644</b>	<b>109</b>	<b>5,982</b>

\* Q3 FY13 normalized to the FY13 annual effective tax rate and Q3 FY12 normalized to the FY12 annual effective tax rate

**Note:** The above presented unaudited consolidated income statement for 3 months ended 31 December 2012 is based on the financial submissions to be made with the US SEC in the form 6K. A charge of Rs 20.4 crs towards fuel surcharge adjustment was accounted in Q2 FY13 after the unaudited results were announced as a subsequent event adjustment since the related judgement of AP High Court was delivered before the filing of Form 6K with US SEC for Q2 FY13 financials. However, in the financials submitted to SEBI this charge has been considered in Q3 FY13 only.

## Table of Contents

### SEGMENTAL ANALYSIS

#### Global Generics

Revenues from Global Generics segment for Q3 FY13 at 20.8 billion, recorded YoY growth of 24%<sup>#</sup> driven by key markets of North America and the Emerging market territories.

Revenues from **North America** for Q3 FY13 at 9.2 billion (\$178 Mn), recorded YoY growth of 38%<sup>#</sup>.

Growth is largely driven by key limited competition products of ziprasidone, tacrolimus, fondaparinux and ramp-up in antibiotics portfolio.

Continued focus on gaining market shares in new products such as atorvastatin, metoprolol, ibandronate and montelukast granules during the quarter.

31 products from the prescription portfolio are ranked among the Top 3 in their respective market shares. *(Source: IMS Health Volumes, November 2012)*

During the quarter, 4 ANDAs were filed. Cumulatively, 65 ANDAs are pending for approval with the USFDA of which 35 are Para IVs and 8 have First To File status.

Revenues from **Russia and Other CIS** markets for Q3 FY13 at 4.4 billion recorded YoY growth of 32%.

Revenues from **Russia** for Q3 FY13 at 3.7 billion recorded YoY growth of 35%, largely aided by seasonal offtake across major brands and new product launches.

Revenues from **Other CIS** markets for Q3 FY13 at 0.7 billion recorded YoY growth of 19%.

Revenues from **India** for Q3 FY13 at 3.7 billion recorded YoY growth of 12%.

Biosimilars portfolio grew YoY by 47% during the quarter.

8 new brands were launched during the quarter.

Revenues from **Europe** for Q3 FY13 at 1.9 billion declined YoY by 20%.

#### **Pharmaceutical Services and Active Ingredients (PSAI)**

## Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

Revenues from PSAI for Q3 FY13 at 7.1 billion, recorded YoY growth of 28%.

During the quarter, 13 DMFs were filed globally, including 3 in the US and 1 in Europe. The cumulative number of DMF filings as of December 31, 2012 is 566.

# *Excluding the impact of the olanzapine profit share recorded in Q3 FY12*



**Table of Contents**

**INCOME STATEMENT HIGHLIGHTS:**

Gross profit margin is at 53% in Q3 FY13. Gross profit margin for Global Generics and PSAI business segments are at 60% and 29% respectively.

Selling, General and Administration (SG&A) expenses for Q3 FY13 including amortization at 8.6 billion increased YoY by 12%.

Research & development expenses for Q3 FY13 at 2.0 billion is at 7% of revenues.

Net Finance expense is at 96 million, in Q3 FY13 compared to the net finance income of 174 million in Q3 FY12. The change is on account of :

Net decline in the forex benefit primarily on account of the loss on time value of options, due to the recent depreciation in the rupee.

Incremental Interest income of 168 million primarily on account of higher interest income from Fixed Deposit and mutual funds.

EBITDA for Q3 FY13 is 6.0 billion, 21% of revenues.

Profit after Tax in Q3 FY13 at 3.8 billion, 13% of revenues.

\*Adjusted Profit after tax in Q3 FY13 at 3.6 billion, 13% of revenues.

Diluted earnings per share in Q3 FY13 are 22.2.

Capital expenditure for Q3 FY13 is 1.5 billion.

\* *Adjusted for tax normalization on account of the annual effective tax rate*

**Table of Contents***All figures in millions**All US dollar figures based on convenience translation rate of 1USD = 54.86***Appendix 1: Key Balance Sheet Items**

Particulars	As on 31st Dec 12		As on 30th Sep 12	
	(\$)	( )	(\$)	( )
Cash and cash equivalents	424	23,264	376	20,641
Trade receivables	490	26,873	478	26,247
Inventories	422	23,169	399	21,885
Property, plant and equipment	659	36,126	643	35,300
Goodwill and Other Intangible assets	226	12,436	224	12,297
Loans and borrowings (current & non current)	672	36,825	636	34,901
Trade payables	200	10,996	190	10,412
Equity	1,217	66,789	1,155	63,354

**Appendix 2: Revenue Mix by Segment**

Segment	Q3 FY13			Q3 FY12			Growth %
	(\$)	( )	%	(\$)	( )	%	
<b>Global Generics</b>	<b>380</b>	<b>20,828</b>	<b>73</b>	<b>388</b>	<b>21,287</b>	<b>77</b>	<b>(2)</b>
North America		9,243	44		11,114	52	(17)
Europe		1,931	9		2,426	11	(20)
India		3,718	18		3,333	16	12
Russia & Other CIS		4,380	21		3,317	16	32
RoW		1,556	7		1,097	5	42
<b>PSAI</b>	<b>130</b>	<b>7,127</b>	<b>25</b>	<b>101</b>	<b>5,563</b>	<b>20</b>	<b>28</b>
North America		1,266	18		1,170	21	8
Europe		2,472	35		1,652	30	50
India		1,268	18		862	15	47
RoW		2,121	30		1,880	34	13
<b>Proprietary Products &amp; Others</b>	<b>13</b>	<b>696</b>	<b>2</b>	<b>15</b>	<b>841</b>	<b>3</b>	<b>(17)</b>
<b>Total</b>	<b>522</b>	<b>28,651</b>	<b>100</b>	<b>505</b>	<b>27,691</b>	<b>100</b>	<b>3</b>

**Table of Contents**

All figures in millions, except EPS

All US dollar figures based on convenience translation rate of 1USD = 54.86

**Appendix 3: Consolidated Income Statement**

Particulars	9 months FY13			9 months FY12			Growth	
	(\$)	( )	%	(\$)	( )	%	%	
<b>Revenues</b>	<b>1,510</b>	<b>82,866</b>	<b>100</b>	<b>1,279</b>	<b>70,153</b>	<b>100</b>	<b>18</b>	
Cost of revenues	713	39,133	47	562	30,818	44	27	
<b>Gross profit</b>	<b>797</b>	<b>43,733</b>	<b>53</b>	<b>717</b>	<b>39,335</b>	<b>56</b>	<b>11</b>	
<b>Operating Expenses</b>								
Selling, general and administrative expenses	453	24,862	30	395	21,651	31	15	
Research and development expenses	97	5,347	6	76	4,170	6	28	
Impairment loss on goodwill and intangible assets	12	688	1	0	0	0	0	
Other operating (income) / expense	(15)	(848)	(1)	(10)	(567)	(1)	50	
<b>Results from operating activities</b>	<b>249</b>	<b>13,684</b>	<b>17</b>	<b>257</b>	<b>14,081</b>	<b>20</b>	<b>(3)</b>	
Net finance (income) / expense	(1)	(63)	(0)	(1)	(78)	(0)	(20)	
Share of (profit) / loss of equity accounted investees	(1)	(79)	(0)	(1)	(43)	(0)	84	
<b>Profit before income tax</b>	<b>252</b>	<b>13,826</b>	<b>17</b>	<b>259</b>	<b>14,202</b>	<b>20</b>	<b>(3)</b>	
Income tax expense	50	2759	3	61	3,367	5	(18)	
<b>Profit for the period</b>	<b>202</b>	<b>11,067</b>	<b>13</b>	<b>197</b>	<b>10,835</b>	<b>15</b>	<b>2</b>	
<b>Diluted EPS</b>	<b>1.2</b>	<b>64.95</b>		<b>1.2</b>	<b>63.68</b>		<b>2</b>	

**Appendix 4: Profit Computation:**

EBITDA Computation	9 months FY13		9 months FY12	
	(\$)	( )	(\$)	( )
<b>PBT</b>	252	13,826	259	14,202
Net Interest Expenses / (Income)	(0)	(1)	11	601
Depreciation	51	2,810	48	2,607
Amortization & Impairment	35	1,932	22	1,202
<b>Reported EBITDA</b>	<b>338</b>	<b>18,567</b>	<b>339</b>	<b>18,612</b>

PAT Computation	9 months FY13		9 months FY12	
	(\$)	( )	(\$)	( )
<b>PAT (reported)</b>	<b>202</b>	<b>11,067</b>	<b>197</b>	<b>10,835</b>
Adjustments:				
Impairment loss on goodwill and intangible assets	13	688		
Tax adjustment*	(8)	(417)	2	133
<b>Adjusted PAT</b>	<b>207</b>	<b>11,338</b>	<b>199</b>	<b>10,968</b>

\* Adjusted for tax normalization on account of the annual effective tax rate for respective YTD financial years.

## **Table of Contents**

### **Disclaimer**

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

### **About Dr. Reddy s**

Dr. Reddy s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand.

For more information, log on to: [www.drreddys.com](http://www.drreddys.com)

### **CONTACT INFORMATION**

#### **Investors and Financial Analysts:**

Kedar Upadhye at [kedaru@drreddys.com](mailto:kedaru@drreddys.com) / +91-40-66834297

Saunak Savla at [saunaks@drreddys.com](mailto:saunaks@drreddys.com) / +91-40-49002135

Milan Kalawadia (USA) at [mkalawadia@drreddys.com](mailto:mkalawadia@drreddys.com) / +1 908-203-4931

#### **Media:**

S Rajan at [rajans@drreddys.com](mailto:rajans@drreddys.com) / +91-40-49002445

Note: All discussions in this release are based on unaudited consolidated IFRS financials.

**Table of Contents**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DR. REDDY S LABORATORIES LIMITED

(Registrant)

By: /s/ Sandeep Poddar

Name: Sandeep Poddar

Title: Company Secretary

Date: February 14, 2013